Doxanthrine

Doxanthrine
Systematic (IUPAC) name
(6aS,12bR)-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline-2,3-diol
Identifiers
ATC code none
PubChem CID 15981509
ChemSpider 13112900
Chemical data
Formula C16H15NO3
Molar mass 269.295 g/mol
  (verify)

Doxanthrine is a synthetic compound which is a potent and selective full agonist for the dopamine D1 receptor.[1][2] Doxanthrine has been shown to be orally active in producing contralateral rotation in the 6-hydroxy-dopamine rat model of Parkinson's disease.[3]

References

  1. Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (November 2006). "trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist". Journal of Medicinal Chemistry 49 (23): 6848–57. doi:10.1021/jm0604979. PMID 17154515.
  2. Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (February 2009). "Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 19 (2): 138–46. doi:10.1016/j.euroneuro.2008.10.002. PMC: 2636714. PMID 19028082.
  3. McCorvey, JD, Watts VJ, Nichols DE (July 2012). "Comparison of the D1 dopamine full agonists,dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease". Psychopharmacology (Berl) 222 (1): 81–87. doi:10.1007/s00213-011-2625-5. PMID 22222862. Retrieved 22 February 2014.


This article is issued from Wikipedia - version of the Thursday, April 21, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.